Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
Date
2018-02-02Author
Rule, Simon
Jurczak, W
Jerkeman, M
Rusconi, C
Trneny, M
Offner, F
Caballero, D
Joao, C
Witzens-Harig, M
Hess, G
Bence-Bruckler, I
Cho, S-G
Thieblemont, C
Zhou, W
Henninger, T
Goldberg, J
Vermeulen, J
Dreyling, M
Subject
Adenine Antineoplastic Combined Chemotherapy Protocols Follow-Up Studies Humans International Agencies Lymphoma, Mantle-Cell Piperidines Prognosis Pyrazoles Pyrimidines Salvage Therapy Sirolimus Survival Rate
Metadata
Show full item recordCollections
Publisher
Springer Science and Business Media LLC
Place of Publication
England
Journal
Leukemia
Volume
32
Issue
8
Pagination
1799-1803
Author URL
Recommended, similar items
The following license files are associated with this item: